BI Asset Management Fondsmaeglerselskab A S Raises Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

BI Asset Management Fondsmaeglerselskab A S grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 64,888 shares of the medical research company's stock after purchasing an additional 2,272 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Thermo Fisher Scientific were worth $32,288,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cypress Advisory Group LLC purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth $253,000. Mondrian Investment Partners LTD increased its stake in Thermo Fisher Scientific by 146.1% in the first quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after purchasing an additional 127,357 shares during the period. GAMMA Investing LLC increased its stake in Thermo Fisher Scientific by 22.0% in the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after purchasing an additional 877 shares during the period. Deutsche Bank AG grew its position in shares of Thermo Fisher Scientific by 9.5% during the 4th quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock worth $687,553,000 after buying an additional 114,277 shares in the last quarter. Finally, Hancock Whitney Corp grew its position in shares of Thermo Fisher Scientific by 0.6% during the 4th quarter. Hancock Whitney Corp now owns 5,386 shares of the medical research company's stock worth $2,802,000 after buying an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO stock traded up $16.4780 during trading on Friday, reaching $500.2380. The company had a trading volume of 1,778,365 shares, compared to its average volume of 2,406,376. The firm has a 50-day simple moving average of $443.02 and a 200-day simple moving average of $457.46. The company has a market cap of $188.89 billion, a price-to-earnings ratio of 28.93, a price-to-earnings-growth ratio of 2.58 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue for the quarter was up 2.9% on a year-over-year basis. During the same period last year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on TMO. Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Barclays increased their price target on Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 24th. UBS Group increased their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. HSBC reissued a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Robert W. Baird raised their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average target price of $593.00.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the sale, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $52,037,916.68. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,896 shares of company stock valued at $8,593,838 over the last three months. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.